Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HUMANIGEN, INC.

(HGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HUMANIGEN, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

07/14/2021 | 12:01pm EDT

Item 7.01. Regulation FD Disclosure

On July 14, 2021, Humanigen, Inc. (the "Company") will meet with representatives of Cantor Fitzgerald & Co. to provide a business update. A copy of the presentation to be discussed at this meeting is furnished as Exhibit 99.1 to this report. A copy of the presentation is also available on the Company's website, www.humanigen.com.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the duration and severity of COVID-19 in the United States and around the world and our projections for COVID-19 hospitalizations in 2021 and future years; our projections regarding the need for lenzilumab as a therapeutic if authorized or approved; the commercial potential of lenzilumab and our ability to maintain a single worldwide price in the multiple jurisdictions in which we are seeking marketing authorizations or approvals or otherwise working to sell product prior to formal approvals; the ability of our contract manufacturers to supply expected quantities of product; and our other plans to initiate or participate in planned clinical trials and otherwise explore the effectiveness of lenzilumab and other candidates in our development portfolio as therapies for other inflammation and immune-oncology indications. These forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in the Company's lack of profitability and need for additional capital to grow its business; the Company's dependence on partners to further the development of its product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorization and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Humanigen's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this filing. The Company undertakes no obligation to revise or update any forward-looking statements made in this filing to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.




Certain Information



The information in this Item 7.01, including Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, except to the extent expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





 (d) Exhibits




Exhibit No.   Exhibit Description

99.1            Humanigen July 14, 2021 Investor Presentation

© Edgar Online, source Glimpses

All news about HUMANIGEN, INC.
09/20SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Human..
PR
09/14HUMANIGEN, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/14HUMANIGEN : Announces Participation and Presentation at Multiple Conferences in September
BU
09/14HUMANIGEN : Bryan Garnier Downgrades Humanigen to Neutral from Buy, Adjusts Price Target t..
MT
09/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/10HUMANIGEN : FDA Declines Humanigen's Application for Lenzilumab Emergency Use Authorizatio..
MT
09/10HUMANIGEN : Jefferies Downgrades Humanigen to Hold from Buy, Adjusts Price Target to $9 fr..
MT
09/10NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/10HUMANIGEN : FDA has committed to working with Humanigen in the development of lenzilumab a..
PU
09/10HUMANIGEN, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on HUMANIGEN, INC.
More recommendations
Financials (USD)
Sales 2021 32,9 M - -
Net income 2021 -205 M - -
Net cash 2021 17,7 M - -
P/E ratio 2021 -1,82x
Yield 2021 -
Capitalization 380 M 380 M -
EV / Sales 2021 11,0x
EV / Sales 2022 3,31x
Nbr of Employees 10
Free-Float 78,1%
Chart HUMANIGEN, INC.
Duration : Period :
Humanigen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUMANIGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 6,39 $
Average target price 21,13 $
Spread / Average Target 231%
EPS Revisions
Managers and Directors
Cameron Durrant Chairman & Chief Executive Officer
Timothy E. Morris Chief Operating & Financial Officer
Dale B. Chappell Director & Chief Scientific Officer
Omar Ahmed Senior VP-Clinical, Medical & Scientific Affairs
Adrian Kilcoyne Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
HUMANIGEN, INC.-64.17%372
CSL LIMITED9.61%101 668
WUXI BIOLOGICS (CAYMAN) INC.18.19%66 051
SAMSUNG BIOLOGICS CO.,LTD.12.95%51 980
BIOGEN INC.21.90%44 485
ALEXION PHARMACEUTICALS, INC.0.00%40 336